Drugs in Development
All Data
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 01, 2020
Details:
Moderna plans to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): V-306
Therapeutic Area: Infections and Infectious Diseases Product Name: V-306
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
All 20 subjects received the first dose of V-306 or placebo, as planned and early clinical experience is encouraging with no adverse events reported to date.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RG6217
Therapeutic Area: Infections and Infectious Diseases Product Name: RG6217
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
Roche has canned a phase 1 test of a potential hepatitis B antiviral as part of its third-quarter clean-up of unwanted pipeline drugs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): V-306
Therapeutic Area: Infections and Infectious Diseases Product Name: V-306
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 16, 2020
Details:
The financing will ensure the company can complete the phase 1 clinical trial of its lead asset V-306 in RSV, advance pre-clinical development of its vaccine candidates against SARS-CoV-2, progress other research collaborations and strengthen the team.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LXE408
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 25, 2020
Details:
Within the scope of the agreement, Novartis is responsible for completing Phase I clinical trials and DNDi will lead Phase II and Phase III development in India.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
